Pivotal Phase III SUNMO study demonstrated an 11.5 month median progression-free survival – three times longer than R-GemOx – ...

The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic ...

Virtual webinar on June 23, 2025 at 8:00 am ETNEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or A ...

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

Currently, Alphamab trades at a price-to-earnings (P/E) ratio of 44 times, even higher than the 30 times for Henlius Biotech ...

Researchers at Araris Biotech AG have developed antibody-drug conjugate (ADC) technology that allows single-step connection of antibody to drug via a novel RKAA peptide linker that stably prevents the ...

Erika Hamilton, MD, discusses the mechanism of action of emiltatug ledadotin, a B7-H4-directed Dolasynthen antibody-drug conjugate.

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

The companies aim to generate preclinical proof-of-concept data on SRB123 and quickly take it into clinical trials.